No Data
Hunan Jiudian Pharmaceutical (300705.SZ): First buyback of 0.3 million shares, involving an investment of 4.9946 million yuan.
On March 14, Gelonghui reported that Hunan Jiudian Pharmaceutical (300705.SZ) announced that on March 13, 2025, the company will implement a share repurchase for the first time through a dedicated repurchase securities account via centralized bidding. The number of shares to be repurchased is 0.3 million shares, accounting for 0.06% of the company's current total share capital, with a highest Fill Price of 16.76 yuan/share, a lowest Fill Price of 16.52 yuan/share, and a total transaction amount of 4.994632 million yuan (excluding transaction costs).
Hunan Jiudian Pharmaceutical (300705.SZ): Ornidazole injection has obtained the Pharmaceutical registration certificate.
On March 14, Glonghui reported that Hunan Jiudian Pharmaceutical (300705.SZ) announced the recent receipt of the "Pharmaceutical Registration Certificate" for Ornidazole Injection issued by the National Medical Products Administration. Ornidazole Injection was developed by Roche Pharmaceuticals and was first launched in the Swiss Franc in 1980, subsequently approved for sale in several European countries for the preoperative prevention and postoperative treatment of anaerobic bacterial infections, as well as severe amoebic disease of the intestine and liver. Nitroimidazoles are one of the first-choice medications for the prevention and treatment of anaerobic bacterial infections, with Ornidazole being the third generation of nitroimidazole drugs marketed after Metronidazole and Tinidazole, exhibiting clear efficacy and applicability compared to similar medications.
Hunan Jiudian Pharmaceutical Co., Ltd.'s (SZSE:300705) Market Cap Increased by CN¥461m, Insiders Receive a 47% Cut
Hunan Jiudian Pharmaceutical (300705.SZ) major shareholder Duan Lixin has completed a Shareholding of 1.13%.
Hunan Jiudian Pharmaceutical (300705.SZ) announced that the Shareholder Duan Lixin has cumulatively reduced his Shareholding by 55 shares.
Hunan Jiudian Pharmaceutical will no longer monopolize the market? Leming Luosuolofen Sodium Gel Patch has been approved, and experts predict it will accelerate the Industry review process.
① Lemin Pharmaceutical's loxoprofen sodium gel patch has officially been approved, marking it as the first to pass the consistency evaluation for approval. From this point on, the market monopoly held by Hunan Jiudian Pharmaceutical has been broken. ② Experts say this indicates new progress in the review process, marking a trend toward a unified standard for the consistency evaluation of external patches, which will result in more pharmaceutical companies being reviewed and approved.
Hunan Jiudian Pharmaceutical (300705.SZ): The controlling Shareholder Zhu Zhihong intends to increase Shareholding by 10 million to -20 million yuan in the company.
On January 17, Gelonghui reported that Hunan Jiudian Pharmaceutical (300705.SZ) announced that the company's controlling shareholder, actual controller, and Chairman, Mr. Zhu Zhihong, plans to increase his shareholding in the company within 6 months from the date of the announcement. He intends to use his own funds to conduct purchases through the concentrated bidding trading system of the Shenzhen Securities Exchange, with a total amount to be increased no less than 10 million yuan (inclusive) and no more than 20 million yuan (inclusive).
Risks To Shareholder Returns Are Elevated At These Prices For Hunan Jiudian Pharmaceutical Co., Ltd. (SZSE:300705)
